We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of ADAP yet.

ADAP Hedge Fund Activity: Q1 2026 in Review

1 of the 8,131 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2026, worth a combined $72 — down 100% from $79.7K a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ADAP and 0 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Josh Arnold Investment Consultant, exiting entirely with an estimated $37.8K sold.

  • 1 institutional investor held Adaptimmune Therapeutics (ADAP) as of Q1 2026, down from 10 in Q4 2025.
  • Funds reported $72 of Adaptimmune Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Adaptimmune Therapeutics positions in Q1 2026 and 9 closed out, a net change of -9 holders.
  • The largest Adaptimmune Therapeutics seller in Q1 2026 was Josh Arnold Investment Consultant, an estimated $37.8K sold.

Based on aggregated 13F filings for Q1 2026.